U.S. adoption of ProFound AI™, the Company’s deep-learning
cancer detection software solution for digital breast tomosynthesis, gaining

call today at 8:30 a.m. ET 


NASHUA, N.H. – May 7,
2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today reported financial results for the three months ended March 31, 2019.


First Quarter 2019

  • Total
    revenue of approximately $6.7 million, an increase of 7% over first quarter of
  • Gross
    profit of $5.3 million, or 78% in the first quarter of 2018 as compared to $4.5
    million or 71% in the first quarter of 2018.
  • GAAP
    Net Loss of $3.7 million, or ($0.22) per diluted share, which includes a $2.5
    million non-cash charge associated with the fair value accounting treatment of the
    Q4, 2018 convertible debentures
  • Non-GAAP Adjusted EBITDA loss of ($0.6) million
    compared to non-GAAP Adjusted EBITDA loss of ($2.4) million in the first
    quarter of 2018.

View Webcast

Full Results